Camille Samuels is a Partner at Venrock. Over the course of her venture career, Cami has been lucky enough to serve as a board member or observer on a variety of successful companies, including Corvidia (acquired by Novo), Genomic Health (GHDX), Kythera (acq. by Allergan), Novacardia (acq. by Merck), RegenXBIO (RGNX), and Spirox (sold to Entellus/Stryker). Prior to Venrock, Cami was a Managing Director at Versant Ventures.
Before Versant, she was responsible for business development at Tularik and worked in corporate development at Genzyme and Millennium Predictive Medicine. She also worked at LEK Consulting.
Cami studied Biology at Duke and received an MBA from Harvard, where she graduated as a Baker Scholar. She is an Aspen Institute Henry Crown Fellow.